Overview

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

Status:
Completed

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

This study compared 3 different three-drug combinations in HIV infected individuals starting their first HIV treatment regimens. Participants were recruited from resource-limited areas in Africa, Asia, South America, Haiti, and also from the United States. The study hypothesis was each of the once daily combinations (PI based, or NNRTI based) would not have inferior efficacy compared to the twice daily NNRTI based combination.

Phase:

Phase 4

Details

Lead Sponsor:

AIDS Clinical Trials Group

Collaborator:

National Institute of Allergy and Infectious Diseases (NIAID)

Treatments:

Atazanavir Sulfate
Didanosine
Efavirenz
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Lamivudine
Lamivudine, zidovudine drug combination
Reverse Transcriptase Inhibitors
Tenofovir
Zidovudine